{
    "clinical_study": {
        "@rank": "82260", 
        "arm_group": [
            {
                "arm_group_label": "N-Rephasin\u00ae SAL200", 
                "arm_group_type": "Experimental", 
                "description": "N-Rephasin\u00ae SAL200, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg"
            }, 
            {
                "arm_group_label": "INT200-Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The Objectives of this study is to evaluate the safety, pharmacokinetics and\n      pharmacodynamics  of single dose of N-Rephasin\u00ae SAL200 in healthy male subjects."
        }, 
        "brief_title": "A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin\u00ae SAL200 in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Male Volunteer", 
        "detailed_description": {
            "textblock": "The purposes of this study are to evaluate the pharmacokinetics, and pharmacodynamics and\n      safety of an experimental intravenous medication, N-Rephasin\u00ae SAL200 in healthy male.\n      Participants will include 36 male volunteers. Participants will be grouped according to\n      dosage of N-Rephasin\u00ae SAL200 including placebo (0 mg/kg). Study procedures include: check of\n      vital signs, reporting any experienced side effects, physical examination including\n      assessment of the cardiovascular system, and blood sample collection for monitoring of\n      pharmacokinetics, pharmacodynamics and antibody production etc. Participants will be\n      involved in study related procedures for up to 50 days after injection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subject whose age is 20 ~ 45 at the time of screening visit.\n\n          -  Body weight of \u226550kg and <90kg, while within \u00b120% of the ideal body weight. [ideal\n             body weight(kg) = {height(cm)-100}x 0.9]\n\n          -  Subject agreed to participate in the trial and to follow all of trial-related rules\n             with a full understanding, after having a full account of the trial\n\n        Exclusion Criteria:\n\n          -  Present disease(s) or medical history(ies) which is(are) clinically significant on\n             liver, heart, nervous system, respiratory system, hemato-oncology, cardiovascular or\n             psychopathy.\n\n          -  Diagnosed or suspected infectious disease within 30 days in prior to the\n             administration.\n\n          -  Clinically significantly allergic to drug(s) containing AI of N-Rephasin\u00ae SAL200 or\n             to other drugs including aspirin and antibiotics, or has medical history(ies) on such\n             allergy.\n\n          -  Already has taken other drug(s) containing AI of N-Rephasin\u00ae SAL200.\n\n          -  Positive for Antibody of N-Rephasin\u00ae SAL200.\n\n          -  SBP\u226490mmHg or DBP\u226450mmHg, otherwise, SBP\u2265150mmHg or DBP\u2265100mmHg in Vital sign which\n             was measured after taking 3 minutes of resting in sitting position.\n\n          -  Has medical history of drug abuse or positive to drug abuse in urine drug screening.\n\n          -  Has taken any prescription drug(s) or herbal medicine(s) within 14 days prior to the\n             administration, otherwise, any OTC(s) or vitamin(s) within 7 days prior to the\n             administration(However, can participate in the study if investigator makes a decision\n             that the subject can participate regardless the drug taken).\n\n          -  Has taken any other study drugs within 2 months prior to the administration.\n\n          -  Has donated blood(whole blood donation or component transfusion) within (2 months or\n             1 month, respectively) in prior to the administration, otherwise, has received blood\n             transfusion within 1 month in prior to the administration.\n\n          -  Smoke at present or positive to metabolism of nicotine in urine test.\n\n          -  Drink regularly(over 21 units/week, 1 unit= 10 g of pure alcohol), otherwise, is not\n             able to interrupt drinking and smoking in study period.\n\n          -  Investigator made a decision that the subject is not eligible based on results of\n             laboratory test or other reason.\n\n          -  Not agree with contraception for 60days after the administration, otherwise,\n             notification of pregnancy in case of his partner is pregnant for 90 days after the\n             administration."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855048", 
            "org_study_id": "SAL200-1A"
        }, 
        "intervention": [
            {
                "arm_group_label": "N-Rephasin\u00ae SAL200", 
                "description": "continuous intravenous infusion over 60 minutes", 
                "intervention_name": "N-Rephasin\u00ae SAL200", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "INT200-Placebo", 
                "description": "Formulation buffer for continuous intravenous infusion over 60 minutes", 
                "intervention_name": "INT200-Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "N-Rephasin\u00ae SAL200", 
            "endolysin", 
            "Placebo"
        ], 
        "lastchanged_date": "August 15, 2013", 
        "location": {
            "contact": {
                "email": "nymph223@snu.ac.kr", 
                "last_name": "Seonghae yoon, M.D", 
                "phone": "82-2-2072-4083"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "investigator": {
                "last_name": "In Jin Jang, M.D., Ph. D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Single-dosing, Dose-escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin\u00ae SAL200 After Continuous Intravenous Infusion in Healthy Male Volunteers", 
        "overall_contact": {
            "email": "ijjang@snu.ac.kr", 
            "last_name": "In Jin Jang, M.D., Ph. D.", 
            "phone": "82-2-740-8290"
        }, 
        "overall_contact_backup": {
            "email": "nymph223@snu.ac.kr", 
            "last_name": "Seonghae Yoon, M.D", 
            "phone": "82-2-2072-1666"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "In Jin Jang, M.D., Ph. D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "12-lead ECGs will be obtained using an ECG machine that automatically calculates the heart rate and measures ventricular rate (/min), PR interval (msec), QRS duration (msec), QT/QTc interval (msec) etc.\nVital sign measurement: blood pressure, pulse rate and body temperature measurement.\nClinical laboratory test: hematological values (WBC with differential count, RBC, hemoglobin, hematocrit, platelet), coagulation values (PT (INR), aPTT), serum biochemical values (calcium, phosphorus, glucose, BUN, uric acid, cholesterol, total protein, albumin, total bilirubin, direct bilirubin, alkaline phosphatase, AST, ALT, \u03b3-GT, CPK, LDH, creatinine, sodium, potassium, chloride), and urinalysis values (specific gravity, pH, albumin, glucose, ketone, bilirubin, blood, nitrite, urobilinogen, WBC, color, turbidity, with microscopy)", 
            "measure": "Evaluation of the safety of N-Rephasin\u00ae SAL200 in healthy human volunteers by 12 lead electrocardiogram, clinical laboratory values changes, monitoring of vital signs, and the occurrence of adverse events.", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 50 days after administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855048"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PK sampling is performed by specified timepoints in the protocol(pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24hrs-post dose).\nParticipants will be followed for the duration of hospital stay.", 
                "measure": "Pharmacokinetic evaluation of N-Rephasin\u00ae SAL200 at the administered doses by analysis of concentration of N-Rephasin\u00ae SAL200 in serum", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to 2"
            }, 
            {
                "description": "Blood sampling will be performed by specified time-points in the protocol (1, 1.5, 2hrs-post dose).\nDetermination of serum antibacterial activity (micrograms per millilitre) of N-Rephasin\u00ae SAL200 will be accessed by qualitative comparison of halos formed after spotting blood samples onto the lawn of Staphylococcus aureus with those formed after spotting standards (0 ug/ml, 0.05 ug/ml, 0.1 ug/ml, 0.2 ug/ml, 0.4 ug/ml, 0.6 ug/ml, 0.8 ug/ml and 1 ug/ml), which are prepared by spiking of N-Rephasin\u00ae SAL200 into human serum.\nParticipants will be followed for the duration of hospital stay.", 
                "measure": "Monitoring of serum antibacterial activity (micrograms per millilitre) of N-Rephasin\u00ae SAL200 over time at the administered doses by spot overlay method (i.e., antibacterial activity assay) using blood samples.", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "Blood sampling for analysis of production of anti-N-Rephasin\u00ae SAL200 antibody is performed at day 50 after administration.\nAnalysis is performed by specified protocol based on ELISA method.", 
                "measure": "Immunogenicity evaluation of N-Rephasin\u00ae SAL200 at the administered doses by analysis of concentration of anti-N-Rephasin\u00ae SAL200 antibody in serum", 
                "safety_issue": "Yes", 
                "time_frame": "Day 50 after administration"
            }
        ], 
        "source": "Intron Biotechnology, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Intron Biotechnology, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}